CAPR
Capricor Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.40
+1.29%Sep 1, 2026, 16:14 UTC
Capricor Therapeutics shares rose 3.48% to $10.26 after an analyst raised the price target to $25 from $2.
Source:Aug 24, 2026, 13:25 UTC
The U.S. FDA extended the PDUFA target action date for Capricor Therapeutics' deramiocel Biologics License Application to November 22, 2026, as it continues review following submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication.
Aug 24, 2026, 06:27 UTC
A class action lawsuit was filed against Capricor Therapeutics, Inc. for alleged violations of U.S. securities laws, and the DJS Law Group is reminding investors of their rights to seek lead plaintiff appointment.
Aug 21, 2026, 11:52 UTC
Kaos Capital Ltd., a shareholder in Capricor Therapeutics Inc., issued a letter calling for an immediate board meeting and proposing governance changes, including nominating two independent directors and creating an M&A committee.
Source:Aug 20, 2026, 10:30 UTC
Capricor Therapeutics is facing a near-certain FDA rejection of its cell therapy deramiocel for Duchenne muscular dystrophy, and has submitted results from an open-label extension of its failed Phase 3 study in an attempt to stave off the rejection.
Source:Aug 17, 2026, 05:17 UTC
Goldman Sachs increased its stake in Capricor Therapeutics by 73% to 1.58 million shares valued at $38 million, and disclosed holdings in Sellas Life Sciences and ImmunityBio totaling nearly $75 million.
Source:Aug 16, 2026, 23:55 UTC
A securities fraud class action lawsuit was filed against Capricor Therapeutics, Inc. alleging material misstatements and/or omissions concerning its lead product candidates' statistical analysis plan and FDA compliance, with a class period from December 17, 2025 through July 26, 2026.
Aug 14, 2026, 10:39 UTC
The U.S. Food and Drug Administration agreed to review new data on Capricor Therapeutics' experimental Duchenne muscular dystrophy drug, causing Capricor shares to more than double in premarket trading on Friday.
Source:Aug 13, 2026, 23:04 UTC
Capricor Therapeutics announced that its biologics license application for deramiocel remains under FDA review and that it plans to submit an amendment seeking a refined indication for upper limb skeletal muscle function in Duchenne muscular dystrophy.
Aug 13, 2026, 20:05 UTC
Capricor Therapeutics reported its financial results for the second quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of approximately $238 million as of that date.
Source:Aug 11, 2026, 12:30 UTC
A class action lawsuit has been filed against Capricor Therapeutics, Inc. on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026.
Aug 3, 2026, 05:00 UTC
A class action lawsuit was filed against Capricor Therapeutics, Inc. for alleged securities law violations under the Securities Exchange Act of 1934.
Jul 31, 2026, 06:00 UTC
The Law Offices of Frank R. Cruz filed a securities fraud lawsuit against Capricor Therapeutics, Inc. related to alleged changes to a statistical analysis plan disclosed by the FDA.
Source:Jul 30, 2026, 03:35 UTC
An FDA advisory panel voted 9-3 against Capricor Therapeutics' Deramiocel for treating Duchenne muscular dystrophy.
Jul 27, 2026, 12:27 UTC
FDA staff reviewers raised concerns about the effectiveness evidence for Capricor Therapeutics' cell therapy deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy, as disclosed in briefing documents released on Monday.
Jul 14, 2026, 00:00 UTC
Capricor Therapeutics signed a commercial lease agreement with ARE-SD Region No. 39 Owner, LLC for approximately 171,000 rentable square feet of space in San Diego, California, to serve as its new headquarters, with a lease term ending 138 months after rent commencement and initial base rent of about $958,000 per month.